Document Type : Original Article
Authors
1 Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
2 Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Abstract
BACKGROUND AND AIM: Bipolar disorder (BD) is one of the most challenging psychiatric disorders
in the management area that can lead to functional, occupational, and cognitive disorders. Without
proper care, this complication can lead to profound psychological challenges and even death. The
aim of this study is to design a minimum data set (MDS) for BD.
MATERIALS AND METHODS: This descriptive cross‑sectional study was conducted in two steps.
In the first step, a survey was conducted in PubMed, Web of Science, and SCOPUS databases to
identify the demographic, managerial, and clinical data elements. Then, the required data elements
were extracted from the studies by the data extraction form and used in a questionnaire. In the
second step, to confirm the data element set, the designed questionnaire was distributed and
collected among 20 psychiatrists and subspecialists during a two‑stage Delphi technique. Descriptive
statistics (frequency and mean) were conducted to analyze the data.
RESULTS: Totally, 112 managerial and clinical data elements in 14 categories were extracted from
the studies. Based on the experts’ opinion and their consensus, 88 necessary data elements were
considered to bipolar MDS. “Medication nonadherence,” “history of suicide,” and “substance abuse
and addiction” were the most important data elements.
CONCLUSION: In this study, an MDS was designed for BD. Providing this MDS, in addition to
improving the clinical processes, it is possible to help electronic system designers and health data
managers to know what information should be included in the health systems or any kind of self‑care
or self‑management software to meet the information needs of these patients.
Keywords
research ed) 2012;345:e8508.
2. Fontana E, Mandolini GM, Delvecchio G, Bressi C, Soares JC,
Brambilla P. Intravenous valproate in the treatment of acute
manic episode in bipolar disorder: A review. J Affect Disord
2020;260:738‑43.
3. Ali Z, Tegin C, El‑Mallakh RS. Evaluating lurasidone as a
treatment option for bipolar disorder. Expert Opin Pharmacother
2020;21:253‑60.
4. MitchellPB, JohnstonAK, CorryJ, BallJR, MalhiGS. Characteristics
of bipolar disorder in an Australian specialist outpatient clinic:
comparison across large datasets. Aust N Z J Psychiatry
2009;43:109‑17.
5. Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression:
A major unsolved challenge. Int J Bipolar Disord 2020;8:1‑13.
6. Sheykhotayefeh M, Safdari R, Ghazisaeedi M, Khademi SH,
Seyed Farajolah SS, Maserat E, et al. Development of a minimum data set (MDS) for C‑section anesthesia information management
system (AIMS). Anesth Pain Med 2017;7:e44132.
7. Moulaei K, Bahaadinbeigy K, Fatehi F. A novel minimum data set
(MDS) for the management of diabetic foot: basis for introducing
effective indicators to the better management, control and
monitoring of diabetic foot. Clinical Diabetology 2021;10:1-12.
8. Zahmatkeshan M, Farjam M, Mohammadzadeh N, Noori T,
Karbasi Z, Mahmoudvand Z, et al. Design of infertility monitoring
system: Minimum data set approach. J Med Life 2019;12:56‑64.
9. Sadoughi F, Shahi M, Ahmadi M, Davaridolatabadi N. The
comparison of the minimum data set for elderly health in selected
countries. Acta Inform Med 2015;23:393‑7.
10. Ahmadi M, Mirbagheri E. Designing data elements and minimum
data set(MDS) for creating the registry of patients with gestational
diabetes mellitus. J Med Life 2019;12:160‑7.
11. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T,
Cipriani A, et al. Evidence‑based guidelines for treating bipolar
disorder: Revised third edition recommendations from the
British Association for Psychopharmacology. J Psychopharmacol
2016;30:495‑553.
12. Fountoulakis KN, Young A, Yatham L, Grunze H, Vieta E, Blier P,
et al. The international college of neuropsychopharmacology
(CINP) treatment guidelines for bipolar disorder in adults
(CINP‑BD‑2017), Part 1: Background and methods of the
development of guidelines. Int J Neuropsychopharmacol
2017;20:98‑120.
13. Rowland TA, Marwaha S. Epidemiology and risk factors for
bipolar disorder. Ther Adv Psychopharmacol 2018;8:251‑69.
14. Potash JB, Toolan J, Steele J, Miller EB, Pearl J, Zandi PP, et al.
The bipolar disorder phenome database: A resource for genetic
studies. Am J Psychiatry 2007;164:1229‑37.
15. American Psychiatric Association A, Association AP. Diagnostic
and Statistical Manual of Mental Disorders: DSM‑5: Washington,
DC: American Psychiatric Association; 2013.
16. Faber‑Wildeboer AT, van Os‑Medendorp H, Kooy A,
Sol‑De Rijk B. Prevalence and risk factors of depression and
diabetes‑related emotional distress in patients with type 2
diabetes: A cross‑sectional study. J Nurs Educ Pract 2013;3:61.
17. Ahmadi M, Alipour J, Mohammadi A, Khorami F. Development
a minimum data set of the information management system for
burns. Burns 2015;41:1092‑9.
18. Greenhouse WJ, Meyer B, Johnson SL. Coping and medication
adherence in bipolar disorder. J Affect Disord 2000;59:237‑41.
19. Scott J. Using health belief models to understand the
efficacy‑effectiveness gap for mood stabilizer treatments.
Neuropsychobiology 2002;46 Suppl 1:13‑5.
20. Ceylan MF, Erdogan B, Tural Hesapcioglu S, Cop E. Effectiveness,
adverse effects and drug compliance of long‑acting injectable
risperidone in children and adolescents. Clin Drug Investig
2017;37:947‑56.
21. Yen CF, Chen CS, Ko CH, Yeh ML, Yang SJ, Yen JY, et al.
Relationships between insight and medication adherence in
outpatients with schizophrenia and bipolar disorder: Prospective
study. Psychiatry Clin Neurosci 2005;59:403‑9.
22. Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R.
Understanding medication non‑adherence in bipolar disorders
using a necessity‑concerns framework. J Affect Disord
2009;116:51‑5.
23. Crowe M, Wilson L, Inder M. Patients’ reports of the factors
influencing medication adherence in bipolar disorder – An
integrative review of the literature. Int J Nurs Stud 2011;48:894‑903.
24. Berk L, Hallam KT, Colom F, Vieta E, Hasty M, Macneil C,
et al. Enhancing medication adherence in patients with bipolar
disorder. Hum Psychopharmacol 2010;25:1‑16.
25. MillerJN, Black DW. Bipolar disorder and suicide: A review. Curr
Psychiatry Rep 2020;22:6.
26. Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ,
Elhaj O, et al. Clinical correlates of patients with rapid‑cycling
bipolar disorder and a recent history of substance use disorder:
A subtype comparison from baseline data of 2 randomized,
placebo‑controlled trials. J Clin Psychiatry 2008;69:1057‑63.
27. Bray JW, Zarkin GA, Dennis ML, French MT. Symptoms of
dependence, multiple substance use, and labor market outcomes.
Am J Drug Alcohol Abuse 2000;26:77‑95.
28. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA,
Bukstein OG, Birmaher B, et al. Treatment development and
feasibility study of family‑focused treatment for adolescents
with bipolar disorder and comorbid substance use disorders.
J Psychiatr Pract 2014;20:237‑48.
29. McCormick U, Murray B, McNew B. Diagnosis and treatment of
patients with bipolar disorder: A review for advanced practice
nurses. J Am Assoc Nurse Pract 2015;27:530‑42.
)